PE20091022A1 - Anticuerpos anti-factor b y sus usos - Google Patents

Anticuerpos anti-factor b y sus usos

Info

Publication number
PE20091022A1
PE20091022A1 PE2008001904A PE2008001904A PE20091022A1 PE 20091022 A1 PE20091022 A1 PE 20091022A1 PE 2008001904 A PE2008001904 A PE 2008001904A PE 2008001904 A PE2008001904 A PE 2008001904A PE 20091022 A1 PE20091022 A1 PE 20091022A1
Authority
PE
Peru
Prior art keywords
factor
antibody
humanized
diabetic
life chain
Prior art date
Application number
PE2008001904A
Other languages
English (en)
Inventor
Menno Van Lookeren Campagne
Laura Deforge
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091022(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091022A1 publication Critical patent/PE20091022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDO A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO 1F7 ANTI-FACTOR B, MONOCLONAL QUIMERICO O HUMANIZADO, EL CUAL SE UNE A UN EPITOPE QUE INCLUYE RESIDUOS DE SITIOS ACTIVOS DEL FACTOR B, Y QUE COMPRENDE LAS SECUENCIAS DE REGION HIPERVARIABLE DE CADENA LIVIANA Y/O PESADA SEGUN SEC ID N°: 1 Y 2 RESPECTIVAMENTE. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO DE AFECCIONES OCULARES ASOCIADAS CON EL COMPLEMENTO, TALES COMO NEOVASCULARIZACION COROIDAL, DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIAS DIABETICAS, EDEMA MACULAR DIABETICO, MIOPIA PATOLOGICA
PE2008001904A 2007-11-08 2008-11-07 Anticuerpos anti-factor b y sus usos PE20091022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08

Publications (1)

Publication Number Publication Date
PE20091022A1 true PE20091022A1 (es) 2009-07-16

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001904A PE20091022A1 (es) 2007-11-08 2008-11-07 Anticuerpos anti-factor b y sus usos

Country Status (15)

Country Link
US (4) US8158762B2 (es)
EP (1) EP2209807A1 (es)
JP (1) JP2011503094A (es)
KR (1) KR20100105587A (es)
CN (1) CN101918444A (es)
AR (1) AR069233A1 (es)
AU (1) AU2008323939A1 (es)
BR (1) BRPI0820343A2 (es)
CA (1) CA2704973A1 (es)
CL (1) CL2008003313A1 (es)
IL (1) IL205577A0 (es)
MX (1) MX2010005115A (es)
PE (1) PE20091022A1 (es)
TW (1) TW200927170A (es)
WO (1) WO2009061910A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
KR20190003951A (ko) * 2016-04-04 2019-01-10 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
US7999082B2 (en) * 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
CA3148917A1 (en) 2006-03-08 2007-09-13 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
KR20090122465A (ko) * 2007-03-01 2009-11-30 어드벤스드 비젼 테라피스, 인코포레이티드 염증성 질환의 치료

Also Published As

Publication number Publication date
AR069233A1 (es) 2010-01-06
US20090123469A1 (en) 2009-05-14
MX2010005115A (es) 2010-05-27
CL2008003313A1 (es) 2010-02-05
BRPI0820343A2 (pt) 2017-08-22
US20120230997A1 (en) 2012-09-13
US20180037667A1 (en) 2018-02-08
CA2704973A1 (en) 2009-05-14
US20160024224A1 (en) 2016-01-28
CN101918444A (zh) 2010-12-15
IL205577A0 (en) 2010-11-30
KR20100105587A (ko) 2010-09-29
TW200927170A (en) 2009-07-01
WO2009061910A1 (en) 2009-05-14
EP2209807A1 (en) 2010-07-28
JP2011503094A (ja) 2011-01-27
US8158762B2 (en) 2012-04-17
AU2008323939A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
PE20091022A1 (es) Anticuerpos anti-factor b y sus usos
PE20190389A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
DOP2014000007A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
BR112014008759A2 (pt) tratamento de doença ocular
PH12020552178A1 (en) Anti-il36r antibodies
PE20190261A1 (es) Anticuerpos que reconocen tau
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
PE20200695A1 (es) Anticuerpos que reconocen tau
PE20161440A1 (es) Variantes del anticuerpo anti-factor d y sus usos
UY37290A (es) Anticuerpos anti-ige
PE20190907A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CR20140047A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20191347A1 (es) Anticuerpos procoagulantes
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
ECSP099379A (es) Anticuerpos anti-factor d humanizados
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
PE20140132A1 (es) Anticuerpo anti-receptor de il-6
PE20130528A1 (es) PROTEINAS QUE SE UNEN AL TNF-alfa

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed